Camacho M, et al. - Investigators analyzed 445 studies to examine the consequences in the intermediate term (1 to <4 years), long-term (4 to <8 years), and very long-term (≥8 years) for maxillomandibular advancement (MMA) as the treatment for obstructive sleep apnea (OSA). They obtained data from the Cochrane Library, Google Scholar, Embase, Cumulative Index to Nursing and Allied Health, and PubMed/MEDLINE. They observed 31 subjects revealed a decline in the apnea-hypopnea index (AHI) from a mean of 48.3 events/h pre-MMA to 8.4 in the intermediate term, 54 showed a reduction in AHI from a mean of 65.8 events/h pre-MMA to 7.7 in the long-term and 35 showed a decline in AHI from a mean of 53.2 events/h pre-MMA to 23.1 in the very long term. They also noted improvement in sleepiness and lowest oxygen saturation in the long-term.